Levothyroxine Treatment Adequacy and Formulation Changes in Patients with Hypothyroidism: A Retrospective Study of Real-World Data from the United States

Background: The prevalence of hypothyroidism (HT) has increased over time. To assess the effectiveness of treatment, we (1) studied thyrotropin (TSH) levels among patients receiving levothyroxine (LT4) and (2) determined the percentages of patients switching among LT4 formulations. Methods: Data on patients with HT receiving LT4 from the Optum™ Clinical and Claims Database were analyzed from March 2013 through February 2020. Eligible adult patients had ‡1 medical claim with an HT diagnosis and all patients were observed for ‡12 months. Patients included in Objective 1 were indexed on a randomly selected TSH result and had ‡2 results for TSH 1–15 months apart. Patients included in Objective 2 were indexed on a randomly selected LT4 pharmacy claim and had ‡2 LT4 claims ‡1 month apart and ‡1 claim during follow-up. Outcomes were the proportion of patients with low, normal, or high (<0.45, 0.45–4.5, or >4.5 mIU/L, respectively) TSH levels and the proportion of patients switching LT4 formulations, respectively. Data were stratified by age group, sex, and insurance type. All data reported were analyzed using descriptive statistics. Results: Of patients who were in the indexed TSH group, 81.1% [confidence intervals: 80.4–81.8; n/N = 9130/ 11,259] achieved normal TSH values. When stratified by age group, sex, and insurance type, ‡70% of patients in each of these subgroups exhibited normal mean TSH values at follow-up. For Objective 2 (N = 25,076), 24.9% (N = 6238) of the LT4-indexed group had ‡1 formulation switch in 12 months, of which 67.3% only switched once, and 41.4% (N = 10,370) had ‡1 formulation switch in up to 24 months. A significantly higher proportion of Medicare vs. commercially insured patients had switched formulations (26.2% vs. 23.1%, p < 0.001). Conclusions: Most LT4-treated patients maintain normal TSH levels, which is an improvement vs. previous reports. Continued physician engagement and patient education are advised to further reduce the number of patients who maintain off-target TSH levels. Contrary to clinical recommendations, about 25% of patients receiving LT4 switched formulations within 1 year, with >40% switching within 2 years; among patients who switched, most only switched once.